Imperial College London
Alternate

ProfessorMatthewPickering

Faculty of Medicine, Department of Immunology and Inflammation

Centre Director, Professor of Rheumatology
 
 
 
//

Contact

 

matthew.pickering Website

 
 
//

Assistant

 

Miss Claudia Rocchi +44 (0)20 3313 2315

 
//

Location

 

9N12Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Prendecki:2021:10.1016/j.xkme.2020.09.010,
author = {Prendecki, M and Clarke, C and McKinnon, T and Lightstone, L and Pickering, MC and Thomas, DC and McAdoo, SP and Willicombe, M},
doi = {10.1016/j.xkme.2020.09.010},
journal = {Kidney Medicine},
pages = {54--59.e1},
title = {SARS-CoV-2 antibody point-of-care testing in dialysis and kidney transplant patients with COVID-19.},
url = {http://dx.doi.org/10.1016/j.xkme.2020.09.010},
volume = {3},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Rationale & Objective: A number of serologic tests for immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now commercially available, including multiple lateral flow immunoassays (LFIAs), which have the advantage of being inexpensive and easy to use, without the reliance on laboratory facilities. However, data on the development of humoral immunity to SARS-CoV-2 in patients with kidney disease is limited, and the utility of an LFIA to test for antibodies in these patients has not been assessed. Study Design: Observational study. Setting & Participants: 60 patients (40 hemodialysis and 20 kidney transplant recipients) with SARS-CoV-2 infection confirmed by viral reverse transcriptase-polymerase chain reaction (RT-PCR) testing and 88 historic negative-control samples (collected before September 2019). Test: A commercially available LFIA to test for SARS-CoV-2 IgG in patients with infection confirmed by viral RT-PCR testing. Outcomes: Sensitivity and specificity of the LFIA to detect SARS-CoV-2 IgG in dialysis patients and transplant recipients. Results: 56/58 (96.6%) patients (38/39 hemodialysis and 18/19 transplant recipients) tested positive for SARS-CoV-2 IgG. 5/7 (71.4%) patients who were negative on preliminary testing had detectable IgG when retested more than 21 days postdiagnosis. Median times to first and second tests after diagnosis were 17 (interquartile range, 15-20) and 35 (interquartile range, 30-39) days, respectively. Calculation of test characteristics gave sensitivity of 96.6% (95% CI, 88.3%-99.4%) and specificity of 97.7% (95% CI, 92.0-99.6%). Limitations: Possible exposure to other beta-coronaviruses that may cross-react with the antigen used in the LFIA cannot be excluded. Conclusions: Symptomatic dialysis patients and transplant recipients commonly develop an immune response against SARS-CoV-2 infection that can be detected using an LFIA. Used diligently, an LFIA could be used to help scre
AU  - Prendecki,M
AU  - Clarke,C
AU  - McKinnon,T
AU  - Lightstone,L
AU  - Pickering,MC
AU  - Thomas,DC
AU  - McAdoo,SP
AU  - Willicombe,M
DO  - 10.1016/j.xkme.2020.09.010
EP  - 59
PY  - 2021///
SN  - 2590-0595
SP  - 54
TI  - SARS-CoV-2 antibody point-of-care testing in dialysis and kidney transplant patients with COVID-19.
T2  - Kidney Medicine
UR  - http://dx.doi.org/10.1016/j.xkme.2020.09.010
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33521621
UR  - https://www.sciencedirect.com/science/article/pii/S2590059520302533?via%3Dihub
UR  - http://hdl.handle.net/10044/1/86247
VL  - 3
ER  -
Download